M. Ullah

发表

Application of the Extended Clearance Classification System (ECCS) in Drug Discovery and Development: Selection of Appropriate In Vitro Tools and Clearance Prediction

N. Parrott, M. Wittwer, S. Fowler, 2020, Drug Metabolism and Disposition.

Toward in vitro-to-in vivo translation of monoclonal antibody pharmacokinetics: Application of a neonatal Fc receptor-mediated transcytosis assay to understand the interplaying clearance mechanisms

C. Funk, S. Dudal, F. Schuler, 2017, mAbs.

Calculation of an Apical Efflux Ratio from P-Glycoprotein (P-gp) In Vitro Transport Experiments Shows an Improved Correlation with In Vivo Cerebrospinal Fluid Measurements in Rats: Impact on P-gp Screening and Compound Optimization

H. Fischer, F. Schuler, Carina Cantrill, 2020, The Journal of Pharmacology and Experimental Therapeutics.

In Vitro Characterization of Axitinib Interactions with Human Efflux and Hepatic Uptake Transporters: Implications for Disposition and Drug Interactions

Caroline A. Lee, E. Reyner, M. Ullah, 2013, Drug Metabolism and Disposition.

Minimizing DILI risk in drug discovery - A screening tool for drug candidates.

T. Singer, C. Funk, K. Youdim, 2015, Toxicology in vitro : an international journal published in association with BIBRA.

Impact of Intracellular Concentrations on Metabolic Drug-Drug Interaction Studies

P. Artursson, N. Parrott, S. Fowler, 2019, The AAPS Journal.

Transport Kinetics, Selective Inhibition, and Successful Prediction of In Vivo Inhibition of Rat Hepatic Organic Anion Transporting Polypeptides

J. Unadkat, B. Tóth, M. Ullah, 2018, Drug Metabolism and Disposition.

DMD051193 1575..1583

E. Reyner, M. Ullah, M. West, 2013 .

Risdiplam distributes and increases SMN protein in both the central nervous system and peripheral organs

S. Bassett, S. Paushkin, J. Alsenz, 2018, Pharmacology research & perspectives.

1 Calculation of an Apical Efflux Ratio from P-glycoprotein (P-gp) In Vitro Transport Experiments Shows an Improved Correlation with In Vivo CSF Measurements in Rats Impact on P-gp Screening and Compound Optimization

H. Fischer, F. Schuler, Carina Cantrill, 2020 .

PBPK models for evaluating membrane transporter mediated DDIs: Current capabilities, case studies, future opportunities and recommendations.

Yuichi Sugiyama, Ming Zheng, Jan Snoeys, 2019, Clinical pharmacology and therapeutics.

Calibration of In Vitro Multidrug Resistance Protein 1 Substrate and Inhibition Assays as a Basis to Support the Prediction of Clinically Relevant Interactions In Vivo

Alexander Hillebrecht, C. Funk, A. Poirier, 2014, Drug Metabolism and Disposition.

The Need for Human Breast Cancer Resistance Protein Substrate and Inhibition Evaluation in Drug Discovery and Development: Why, When, and How?

C. Funk, A. Poirier, M. Ullah, 2014, Drug Metabolism and Disposition.

The evolution of the OATP hepatic uptake transport protein family in DMPK sciences: from obscure liver transporters to key determinants of hepatobiliary clearance

Hugh A Barton, Hannah M Jones, Maurice Dickins, 2012, Xenobiotica; the fate of foreign compounds in biological systems.

Addressing Today’s Absorption, Distribution, Metabolism, and Excretion (ADME) Challenges in the Translation of In Vitro ADME Characteristics to Humans: A Case Study of the SMN2 mRNA Splicing Modifier Risdiplam

Cordula Stillhart, A. Guenther, K. Heinig, 2021, Drug Metabolism and Disposition.

Microsoft Word-39120393-file00.docx

Caroline A. Lee, E. Reyner, M. Ullah, 2013 .

Development of a multiplex UPLC-MRM MS method for quantification of human membrane transport proteins OATP1B1, OATP1B3 and OATP2B1 in in vitro systems and tissues.

N. Sadagopan, M. Ullah, W. Tschantz, 2012, Analytica chimica acta.

Successful Prediction of In Vivo Hepatobiliary Clearances and Hepatic Concentrations of Rosuvastatin Using Sandwich-Cultured Rat Hepatocytes, Transporter-Expressing Cell Lines, and Quantitative Proteomics

Jashvant D. Unadkat, J. Unadkat, B. Tóth, 2018, Drug Metabolism and Disposition.

Entrectinib, a TRK/ROS1 inhibitor with anti-CNS tumor activity: differentiation from other inhibitors in its class due to weak interaction with P-glycoprotein

M. Merchant, Björn Wagner, H. Fischer, 2020, Neuro-oncology.

Impact of Intracellular Concentrations on Metabolic Drug-Drug Interaction Studies

P. Artursson, N. Parrott, S. Fowler, 2019, AAPS Journal.

In vitro and clinical investigations to determine the drug-drug interaction potential of entrectinib, a small molecule inhibitor of neurotrophic tyrosine receptor kinase (NTRK)

S. Fowler, F. Mercier, Kenichi Umehara, 2021, Investigational New Drugs.

Refining the in vitro and in vivo critical parameters for P-glycoprotein, [I]/IC50 and [I2]/IC50, that allow for the exclusion of drug candidates from clinical digoxin interaction studies.

Bo Feng, Ray Liu, Jack A Cook, 2010, Molecular pharmaceutics.

Response to “Breast Cancer Resistance Protein Substrate and Inhibition Evaluation: Why, When, and How?”

C. Funk, A. Poirier, M. Ullah, 2014, Drug Metabolism And Disposition.

J. Unadkat, B. Tóth, M. Ullah, 2018, Drug Metabolism and Disposition.

Simultaneous Assessment of Clearance, Metabolism, Induction, and Drug-Drug Interaction Potential Using a Long-Term In Vitro Liver Model for a Novel Hepatitis B Virus Inhibitor

Stephen Fowler, Nicole A. Kratochwil, Florian Klammers, 2018, The Journal of Pharmacology and Experimental Therapeutics.

In Vitro Characterization of Axitinib Interactions with Human Efflux and Hepatic Uptake Transporters: Implications for Disposition and Drug Interactions

Caroline A. Lee, E. Reyner, M. Ullah, 2013, Drug Metabolism and Disposition.

The Need for Human Breast Cancer Resistance Protein Substrate and Inhibition Evaluation in Drug Discovery and Development: Why, When, and How?

C. Funk, A. Poirier, M. Ullah, 2014, Drug Metabolism and Disposition.